Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Phenylalanine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.55 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | GSR | P00390 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL1921315 | 1.00 | SLC7A5 (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1921649 | 0.95 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL20586939 | 0.94 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1921945 | 0.94 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1921946 | 0.94 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| Dl-Phenylalanine SCHEMBL28079151 | 0.92 | SLC7A5 (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL1921833 | 0.91 | SLC7A5 (0.67) | SLC7A5ALPIPKMPTGS1XIAP | |
| Tyrosine SCHEMBL1649464 | 0.90 | SLC7A5 (0.57) | SLC7A5ALPIPKMPTGS1XIAP | |
| Tyrosine SCHEMBL1921493 | 0.90 | SLC7A5 (0.57) | SLC7A5ALPIPKMPTGS1XIAP | |
| Tyrosine SCHEMBL26598018 | 0.90 | SLC7A5 (0.57) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4800481-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-20100298227-A1 | Treatment of autoimmune conditions with Copolymer 1 and related copolymers | President and Fellows of Harvard College and Yeda Research | 2010-11-25 | — | — | US | claimed |
| US-20080207526-A1 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-08-28 | — | — | US | claimed |
| US-20050233948-A1 | Drug complex for treatment of metastatic prostate cancer | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2005-10-20 | — | — | US | claimed |
| US-20030035804-A1 | Drug complex for treatment of metastatic prostate cancer | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2003-02-20 | — | — | US | claimed |
| EP-1098902-A4 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RES & DEV (IL) | 2002-07-24 | — | — | EP | claimed |
| EP-1105414-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | President And Fellows of Harvard College (US) | 2001-06-13 | — | — | EP | claimed |
| EP-1098902-A1 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2001-05-16 | — | — | EP | claimed |
| WO-2000005250-A9 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RES & DEV (IL) | 2000-10-12 | — | — | WO | claimed |
| WO-2000005250-A1 | TREATMENT OF AUTOIMMUNE CONDITIONS WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES | YEDA RESEARCH AND DEVELOPMENT CO., LTD (IL) | 2000-02-03 | — | — | WO | claimed |
| WO-2000005249-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-03 | — | — | WO | claimed |
| WO-2000001419-A1 | DRUG COMPLEX FOR TREATMENT OF METASTATIC PROSTATE CANCER | JCRT RADIATION ONCOLOGY SUPPORT SERVICES, INC. (US) | 2000-01-13 | — | — | WO | claimed |
| US-9066905-B2 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-06-30 | — | — | US | disclosed |
| EP-2848627-A2 | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2015-03-18 | — | — | EP | disclosed |
| EP-2327712-A2 | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2011-06-01 | — | — | EP | disclosed |
| US-7566767-B2 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080207526-A1 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-08-28 | — | — | US | disclosed |
| US-20040006022-A1 | Synthetic peptides and methods of use for autoimmune disease therapies | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-01-08 | — | — | US | disclosed |
| EP-1105414-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | President And Fellows of Harvard College (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000005249-A2 | SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233948-A1 | Drug complex for treatment of metastatic prostate cancer | KLK3, ACP3, FOLH1 | PTGS1 2782/4885SLC7A5 797/4885ALPI 2239/4885 |
| US-20030035804-A1 | Drug complex for treatment of metastatic prostate cancer | KLK3, ACP3, FOLH1 | PTGS1 2782/4885SLC7A5 797/4885ALPI 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.